Repeated oral administration of a cathepsin K inhibitor significantly suppresses bone resorption in exercising horses with evidence of increased bone formation and maintained bone turnover.

This research evaluates the effect of a particular inhibitor on bone resorption and formation in horses during exercise, finding a significant suppression of bone resorption and evidence of increased bone formation without negatively affecting normal bone turnover.

Study Design and Rationale

• The team investigated the use of VEL-0230, a specific irreversible inhibitor of cathepsin K (CatK), a protein involved in bone resorption. The rationale behind this was to observe whether suppression of CatK activity could effectively decrease bone resorption.
• This study comprised of twelve young exercising horses, split randomly into controlled clinical trials. Horses received four weekly doses of either the CatK inhibitor (CatKI) or a vehicle control.

Research Methodology

• The horses were subjected to baseline and post-study nuclear scintigraphy, a technique for imaging the bone’s metabolic activity. The researchers also took blood samples and analyzed plasma bone biomarkers, specifically CTX-1 (a biomarker of bone resorption) and osteocalcin (a marker of bone formation).
• Post-study bone labeling and bone biopsy were performed. The specimens were examined further using microcomputed tomography for detailed 3D imaging and histomorphometry for studying the structure and number of bone tissues.

Key Findings

• The results suggested that the CatKI indeed inhibited plasma CTX-1, indicating a decrease in bone collagen resorption. Moreover, it increased the concentration of bone plasma osteocalcin, implying enhanced bone formation.
• Interestingly, despite the significant changes in biomarker levels indicating altered bone metabolism, it was found that the drug did not apparently disrupt normal bone turnover even during physical activity. This is a positive outcome as it means the drug does not seem to have adverse effects on normal bone health while exerting its inhibitory effect on bone resorption.
• The study didn’t find a significant difference between the bone morphology, density, and rate of formation between the control and treated group.

Implications and Future Research

• This research shows promise for the use of CatKI in controlling and treating bone diseases characterized by excessive bone resorption. It shows that the CatKI, VEL-0230, can inhibit bone resorption while not adversely affecting normal bone turnover, making it a potential candidate for further investigation in the treatment of bone conditions.
• Though these outcomes are promising, further investigation is required to confirm these findings, especially in animals with existing bone diseases to consolidate the evidence about the clinical effectiveness of CatK inhibitors.